ATE542802T1 - Hiv-inhibierende 5-substituierte pyrimidine - Google Patents

Hiv-inhibierende 5-substituierte pyrimidine

Info

Publication number
ATE542802T1
ATE542802T1 AT05789686T AT05789686T ATE542802T1 AT E542802 T1 ATE542802 T1 AT E542802T1 AT 05789686 T AT05789686 T AT 05789686T AT 05789686 T AT05789686 T AT 05789686T AT E542802 T1 ATE542802 T1 AT E542802T1
Authority
AT
Austria
Prior art keywords
hiv
inhibiting
substituted pyrimidines
pyrimidines
substituted
Prior art date
Application number
AT05789686T
Other languages
English (en)
Inventor
Jerome Guillemont
Jan Heeres
Paulus Joannes Lewi
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34929637&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE542802(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Application granted granted Critical
Publication of ATE542802T1 publication Critical patent/ATE542802T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT05789686T 2004-09-30 2005-09-29 Hiv-inhibierende 5-substituierte pyrimidine ATE542802T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04104805 2004-09-30
PCT/EP2005/054932 WO2006035069A1 (en) 2004-09-30 2005-09-29 Hiv inhibiting 5-substituted pyrimidines

Publications (1)

Publication Number Publication Date
ATE542802T1 true ATE542802T1 (de) 2012-02-15

Family

ID=34929637

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05789686T ATE542802T1 (de) 2004-09-30 2005-09-29 Hiv-inhibierende 5-substituierte pyrimidine

Country Status (17)

Country Link
US (1) US8946248B2 (de)
EP (1) EP1797047B1 (de)
JP (1) JP5046943B2 (de)
KR (1) KR20070057837A (de)
CN (1) CN101027288B (de)
AR (1) AR051315A1 (de)
AT (1) ATE542802T1 (de)
AU (1) AU2005288866B2 (de)
BR (1) BRPI0516748B8 (de)
CA (1) CA2575472C (de)
ES (1) ES2380631T3 (de)
IL (1) IL181056A (de)
MX (1) MX2007003796A (de)
RU (1) RU2410379C2 (de)
TW (1) TW200626561A (de)
WO (1) WO2006035069A1 (de)
ZA (1) ZA200702656B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0516746A (pt) * 2004-09-30 2008-09-23 Tibotec Pharm Ltd 5-heterociclil pirimidinas para inibição de hiv
ES2380631T3 (es) 2004-09-30 2012-05-17 Tibotec Pharmaceuticals Pirimidinas sustituidas en posición 5 inhibidoras de VIH
US7935711B2 (en) * 2005-02-18 2011-05-03 Tibotec Pharmaceuticals Ltd. HIV inhibiting 2-(4-cyanophenylamino) pyrimidine oxide derivatives
ES2465666T3 (es) 2006-03-30 2014-06-06 Janssen R&D Ireland Pirimidinas 5-amido-sustituidas inhibidoras del HIV
BRPI0720858B8 (pt) * 2006-12-29 2021-05-25 Janssen R & D Ireland pirimidinas 6-substituídas inibidoras de hiv e composição farmacêutica que as compreende
ES2523863T3 (es) * 2006-12-29 2014-12-02 Janssen R&D Ireland Pirimidinas 5,6-sustituidas inhibidoras del VIH
AU2012245387C1 (en) 2011-04-22 2016-05-05 Signal Pharmaceuticals, Llc Substituted Diaminocarboxamide and Diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
ES2664094T3 (es) * 2012-07-12 2018-04-18 Hetero Research Foundation Procedimiento de preparación de rilpivirina utilizando un intermedio nuevo
SG11201503395TA (en) * 2012-11-08 2015-05-28 Bristol Myers Squibb Co ALKYL AMIDE-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL IN THE MODULATION OF IL-12, IL-23 AND/OR IFNα
NZ715903A (en) 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
ES2877642T3 (es) 2014-12-16 2021-11-17 Signal Pharm Llc Formulaciones de 2-(terc-butilamino)-4-((1R,3R,4R)-3-hidroxi-4-metilciclohexilamino)-pirimidin-5-carboxamida
WO2016100308A1 (en) 2014-12-16 2016-06-23 Signal Pharmaceuticals, Llc Methods for measurement of inhibition of c-jun n-terminal kinase in skin
US20180022710A1 (en) 2015-01-29 2018-01-25 Signal Pharmaceuticals, Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
EP3795553B1 (de) 2015-07-24 2024-05-15 Celgene Corporation Verfahren zur synthese von (1r,2r,5r)-5-amino-2-methylcyclohexanolhydrochlorid und nützliche zwischenprodukte darin

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
DE3881320D1 (de) * 1987-09-28 1993-07-01 Ciba Geigy Ag Schaedlingsbekaempfungsmittel.
EP0862463A1 (de) 1995-11-23 1998-09-09 Janssen Pharmaceutica N.V. Feste mischungen von cyclodextrinen, hergestellt durch schmelzextrusionsverfahren
NO311614B1 (no) 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
NZ506679A (en) 1998-03-27 2002-11-26 Janssen Pharmaceutica Nv HIV inhibiting pyrimidine derivatives
EP0945447A1 (de) 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituierte 1,3,5-Triazinderivate zur Behandlung von HIV Infektionen
SK287269B6 (sk) * 1998-11-10 2010-05-07 Janssen Pharmaceutica N. V. Derivát pyrimidínu, jeho použitie, spôsob jeho prípravy a farmaceutická kompozícia, kombinácia a produkt s jeho obsahom
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
JP5230050B2 (ja) * 2000-05-08 2013-07-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｈｉｖ複製阻害剤
HUP0400639A3 (en) 2000-12-21 2010-03-29 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
AU2003296760B2 (en) 2002-11-15 2009-11-19 Tibotec Pharmaceuticals Ltd. Substituted indolepyridinium as anti-infective compounds
US7504396B2 (en) 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
KR20070057798A (ko) 2004-09-30 2007-06-07 티보텍 파마슈티칼즈 리미티드 Ｈｉｖ를 저해하는 5-탄소환 또는 복소환으로 치환된피리미딘
ES2380631T3 (es) 2004-09-30 2012-05-17 Tibotec Pharmaceuticals Pirimidinas sustituidas en posición 5 inhibidoras de VIH
BRPI0516746A (pt) 2004-09-30 2008-09-23 Tibotec Pharm Ltd 5-heterociclil pirimidinas para inibição de hiv
ES2465666T3 (es) 2006-03-30 2014-06-06 Janssen R&D Ireland Pirimidinas 5-amido-sustituidas inhibidoras del HIV
ES2523863T3 (es) 2006-12-29 2014-12-02 Janssen R&D Ireland Pirimidinas 5,6-sustituidas inhibidoras del VIH
BRPI0720858B8 (pt) 2006-12-29 2021-05-25 Janssen R & D Ireland pirimidinas 6-substituídas inibidoras de hiv e composição farmacêutica que as compreende

Also Published As

Publication number Publication date
JP5046943B2 (ja) 2012-10-10
IL181056A (en) 2014-02-27
TW200626561A (en) 2006-08-01
CN101027288A (zh) 2007-08-29
KR20070057837A (ko) 2007-06-07
MX2007003796A (es) 2007-04-25
RU2007116172A (ru) 2008-11-10
BRPI0516748A (pt) 2008-09-23
CA2575472C (en) 2013-07-30
BRPI0516748B8 (pt) 2021-05-25
CA2575472A1 (en) 2006-04-06
JP2008514681A (ja) 2008-05-08
AU2005288866B2 (en) 2012-07-26
IL181056A0 (en) 2007-07-04
BRPI0516748B1 (pt) 2019-11-19
AR051315A1 (es) 2007-01-03
EP1797047A1 (de) 2007-06-20
RU2410379C2 (ru) 2011-01-27
WO2006035069A1 (en) 2006-04-06
US8946248B2 (en) 2015-02-03
ES2380631T3 (es) 2012-05-17
ZA200702656B (en) 2008-08-27
CN101027288B (zh) 2013-04-17
EP1797047B1 (de) 2012-01-25
AU2005288866A1 (en) 2006-04-06
US20080262007A1 (en) 2008-10-23

Similar Documents

Publication Publication Date Title
ATE520672T1 (de) Hiv-hemmende 5-carbo- oder heterozyklisch substituierte pyrimidine
ATE529412T1 (de) Herbizide pyrimidine
EP1724267A4 (de) Pyrimidinderivat
EP1890703A4 (de) Pyrimidinverbindungen
NL2000323A1 (nl) Pyrimidine-derivaten.
MA28824B1 (fr) Derives de pyrimidine
EP1546115A4 (de) Substituierte pyrimidine
MA28813B1 (fr) Derives de pyrimidine
EP1968950A4 (de) Pyrimidinkinaseinhibitoren
GB0415364D0 (en) Pyrimidine derivatives
ZA200702656B (en) HIV inhibiting 5-substituted pyrimidines
ATE538130T1 (de) Pyrimidinderivate und ihre verwendung als p2y12- rezeptorantagonisten
GB0415367D0 (en) Pyrimidine derivatives
ATE509011T1 (de) Pyrimidinderivate als 11beta-hsd1-inhibitoren
ATE449080T1 (de) 4-phenyl-6-substituierte pyrimidin-2- carbonitrilderivate
ATE487718T1 (de) Substituierte bizyklische pyrimidonderivate
ATE420646T1 (de) Aminopyrimidine als kinase-modulatoren
ATE366242T1 (de) 5-substituierte chinazolinonderivate
ATE350370T1 (de) 2-substituierte pyrimidine
DE112005002826A5 (de) Ausgleichseinheit
DE602005004472D1 (de) Ausgleichsanordnung
ATE521769T1 (de) Beschlag
IL172845A0 (en) 2-substituted pyrimidines
ITVI20040274A1 (it) Distributore-dosatore di asfalto
AT6947U3 (de) Bob